Literature DB >> 19694795

HLA class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions.

Hiroko Ikeda1, Yukitoshi Takahashi, Etsuko Yamazaki, Tateki Fujiwara, Nahoko Kaniwa, Yoshiro Saito, Michiko Aihara, Mariko Kashiwagi, Masaaki Muramatsu.   

Abstract

Carbamazepine (CBZ) is frequently used for treating epilepsy, but this drug causes cutaneous adverse drug reactions (cADRs) that may range from mild to severe. It is reported recently that the human leukocyte antigen HLA-B*1502 is associated with Stevens-Johnson syndrome (SJS) induced by CBZ in Han Chinese. We examined HLA class I in 15 Japanese patients who fulfilled the diagnostic criteria for CBZ-induced cADRs (mild in 10 and severe = SJS in 5). HLA-B*1518, HLA-B*5901 and HLA-C*0704 alleles showed higher relative risks (above 10.0) for severe cADRs. The haplotype (HLA-A*2402-B*5901-C*0102) had high relative risk (16.09) for severe cADRs. In patients with severe cADRs, frequencies of HLA-A*1101, HLA-A*3303, HLA-B*1501, HLA-B*4403, HLA-B*5101, HLA-B*5201, HLA-C*0702, and HLA-C*1202 alleles are relatively lower than in the Japanese population. These data may suggest that HLA-B*5901 is one of the candidate markers for CBZ-induced SJS in Japanese.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19694795     DOI: 10.1111/j.1528-1167.2009.02269.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  34 in total

1.  External quality assessment for laboratory testing of HLA-B*15:02 allele in relation to carbamazepine therapy.

Authors:  Guigao Lin; Kuo Zhang; Yanxi Han; Jiehong Xie; Jinming Li
Journal:  J Clin Lab Anal       Date:  2017-04-25       Impact factor: 2.352

Review 2.  Pharmacokinetics and Pharmacogenetics of Carbamazepine in Children.

Authors:  Natasa Djordjevic; Slobodan M Jankovic; Jasmina R Milovanovic
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-10       Impact factor: 2.441

Review 3.  Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy.

Authors:  Rebecca Pavlos; Simon Mallal; David Ostrov; Yuri Pompeu; Elizabeth Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2014 Jan-Feb

4.  Drug hypersensitivity: pharmacogenetics and clinical syndromes.

Authors:  Elizabeth J Phillips; Wen-Hung Chung; Maja Mockenhaupt; Jean-Claude Roujeau; Simon A Mallal
Journal:  J Allergy Clin Immunol       Date:  2011-03       Impact factor: 10.793

Review 5.  Recent advances in the understanding of severe cutaneous adverse reactions.

Authors:  N R Adler; A K Aung; E N Ergen; J Trubiano; M S Y Goh; E J Phillips
Journal:  Br J Dermatol       Date:  2017-09-29       Impact factor: 9.302

Review 6.  A review of pharmacogenetics of adverse drug reactions in elderly people.

Authors:  Maurizio Cardelli; Francesca Marchegiani; Andrea Corsonello; Fabrizia Lattanzio; Mauro Provinciali
Journal:  Drug Saf       Date:  2012-01       Impact factor: 5.606

7.  Testing for drug hypersensitivity syndromes.

Authors:  Craig M Rive; Jack Bourke; Elizabeth J Phillips
Journal:  Clin Biochem Rev       Date:  2013-02

Review 8.  Genotyping for severe drug hypersensitivity.

Authors:  Eric Karlin; Elizabeth Phillips
Journal:  Curr Allergy Asthma Rep       Date:  2014-03       Impact factor: 4.806

9.  Association of HLA-B*1502 and *1511 allele with antiepileptic drug-induced Stevens-Johnson syndrome in central China.

Authors:  Dan Sun; Chun-Hua Yu; Zhi-Sheng Liu; Xue-Lian He; Jia-Sheng Hu; Ge-Fei Wu; Bing Mao; Shu-Hua Wu; Hui-Hui Xiang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-02-06

Review 10.  HLAs: Key regulators of T-cell-mediated drug hypersensitivity.

Authors:  A J Redwood; R K Pavlos; K D White; E J Phillips
Journal:  HLA       Date:  2018-01       Impact factor: 4.513

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.